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Introduction: This report describes our experience using a low-dose synthetic adrenocorti-
cotropic hormone (ACTH) analog for patients affected by nephrotic syndrome who had not 
responded to or had relapsed after steroid and immunosuppressive treatments.
Patients and methods: Eighteen adult nephrotic patients with an estimated glomerular 
filtration rate .30 mL/min were recruited. Histological pictures included ten of membranous 
nephropathy, three of membranous proliferative glomerulonephritis, three of minimal change, 
and two of focal segmental glomerular sclerosis. All patients received the synthetic ACTH 
analog tetracosactide 1 mg intramuscularly once a week for 12 months. Estimated glomerular 
filtration rate, proteinuria, serum lipids, albumin, glucose, and potassium were determined 
before and during the treatment.
Results: One of the 18 patients discontinued the treatment after 1 month because of severe fluid 
retention, and two patients were lost at follow-up. Complete remission occurred in six cases, 
while partial remission occurred in four cases (55.5% responder rate). With respect to baseline, 
after 12 months proteinuria had decreased from 7.24±0.92 to 2.03±0.65 g/day (P,0.0001), and 
serum albumin had increased from 2.89±0.14 to 3.66±0.18 g/dL (P,0.0001). Total and low-
density lipoprotein cholesterol had decreased from 255±17 to 193±10 mg/dL (P=0.01), and 
from 168±18 to 114±7 mg/dL (P=0.03), respectively. No cases of severe worsening of renal 
function, hyperglycemia, or hypokalemia were observed, and no admissions for cardiovascular 
or infectious events were recorded.
Conclusion: Tetracosactide administration at the dosage of 1 mg intramuscularly per week for 
12 months seems to be an acceptable alternative for nephrotic patients unresponsive or relaps-
ing after steroid-immunosuppressive regimens. Further studies should be planned to assess the 
effect of this low-dose ACTH regimen also in nephrotic patients not eligible for kidney biopsy 
or immunosuppressive protocols.
Keywords: ACTH, glomerulonephritis, proteinuria, nephrotic syndrome, CKD, Tetracosactide
Introduction
Steroid-immunosuppressive regimens for patients with nephrotic syndrome depend on 
the histological patterns and on the severity of the glomerular damage. Unfortunately, 
in several cases nephrotic syndrome does not reverse or frequently recurs. In addition, 
immunosuppressant and steroid treatments have limitations with regard to duration and 
dosage administration, and may expose patients to mild-to-severe side effects.1–6
Among possible pharmacological treatments of nephrotic syndrome, adrenocorti-
cotropic hormone (ACTH) or the synthetic ACTH analog tetracosactide (Figure 1) has 
raised new interest, because of its noncorticosteroid mechanism of action,7,8 namely 
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direct melanocortin receptor-mediated immunomodulation 
and podocyte protection.9
ACTH was employed many years ago for the treatment 
of nephrotic syndrome in children and adults.10–12 It has been 
reappraised, due to its efficacy in reducing proteinuria and 
lipids in cases of glomerulonephritis resistant to conven-
tional treatment with steroids and immunosuppressors. This 
effect has persisted for several patients many months after 
the discontinuation of treatment.13–17 Since ACTH action is 
mediated by a protective effect activity on podocytes, it may 
be favorably used in different types of glomerular disease. 
Namely, ACTH reduces foot-process effacement and podo-
cyte apoptosis, and ameliorates the decline in glomerular 
expression of podocyte markers, including vimentin, nephrin, 
and podocin.8
A natural, highly purified ACTH gel has been recently 
employed in the US, and has exhibited a good therapeutic 
effect on proteinuria in idiopathic nephrotic syndrome,18 
advanced diabetic nephropathy with nephrotic-range 
proteinuria,19 and idiopathic membranous nephropathy.20 
This natural form is different from the synthetic ACTH 1–24, 
available outside the US, in terms of pharmacokinetics, 
pharmacodynamics, and physiologic actions. Melanocortin 
peptides, pharmacologically active molecules derived from 
proopiomelanocortin, exist in natural ACTH but not in the 
synthetic form. Similarly, the insulinotropic effect of the 
endogenous hormone is due to the C-terminal ACTH 1–39 
which is omitted from the synthetic analog.21
Synthetic ACTH 1–24 is the form available in Europe, 
and its standard dosage is 1 mg given intramuscularly 
twice a week for 1 year. This schedule was as effective as 
methylprednisolone plus a cytotoxic agent for 6 months 
in idiopathic membranous nephropathy.22 In addition to 
nephrotic syndrome, other potential indications of this drug 
are neurologic diseases (acute exacerbations of multiple 
sclerosis and infantile myoclonic encephalopathy with 
hypsarrhythmia), rheumatologic diseases (acute rheumatic 
fever, rheumatoid arthritis, lupus erythematosus, periar-
teritis nodosa, psoriatic arthritis, scleroderma, rheumatoid 
spondylitis, and Still’s disease), dermatologic diseases 
(exfoliative dermatitis, dermatomyositis, and pemphigus), 
gastrointestinal diseases (regional enteritis and ulcerative 
colitis), and as adjuvant treatment to improve tolerability 
to chemotherapy.
Although ACTH administration is usually well tolerated, 
such side effects as hypokalemia, fluid retention, and hyperg-
lycemia have been reported. This study reports our experience 
of a different ACTH-administration schedule, namely 1 mg 
once a week for 12 months with the aim of reducing side 
effects and increasing tolerability.
Patients and methods
Adult patients affected by nephrotic syndrome who were 
unresponsive or relapsing after immunosuppressive-steroid 
treatment were considered for the study. Patients with per-
sisting nephrotic syndrome or proteinuria reduction less 
than 50% after treatment were defined as “non-responders”, 
whereas patients with a nephrotic syndrome recurrence 
following an initial partial or complete remission were 
considered as “relapsers”. Patients with advanced chronic 
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Figure 1 Chemical structure of tetracosactide.
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kidney disease (stages IV–V), infections, diabetes, glaucoma, 
active cancer, severe hypertension, peptic ulcer, or pregnancy 
were excluded. Eighteen patients were ultimately included. 
The characteristics of the studied population are reported 
in Table 1.
Histological diagnoses were membranous nephropathy 
(MN) in ten cases, membranous proliferative glomerulo-
nephritis (MPGN) in three cases, minimal-change disease 
(MCD) in three cases, and focal segmental glomerular scle-
rosis (FSGS) in two cases.
All patients had previously received different immu-
nosuppressive treatments such as: high-dose prednisolone, 
cyclophosphamide, cyclosporine, and mycophenolate mofetil. 
These drugs were stopped at least 3 months before the first 
ACTH administration (Table 1). Treatment with angiotensin-
converting enzyme inhibitors (ten cases), angiotensin-
receptor blockers (one patient), both angiotensin-converting 
enzyme inhibitors and angiotensin-receptor blockers (five 
patients), and statins (15 patients) remained unmodified. All 
patients received ACTH (synthetic form 1–24) at a dose of 1 
mg intramuscularly once a week for 12 months.
The following parameters were studied before and dur-
ing the 12-month treatment period: arterial blood pressure, 
body weight, estimated glomerular filtration rate, 24-hour 
urinary protein excretion, and serum levels of glucose, gly-
cated hemoglobin, total and low-density lipoprotein (LDL) 
cholesterol, potassium, and albumin. Complete remission was 
defined as stable or improved renal function and urine protein 
excretion ,0.3 g/day. Partial remission was defined as stable 
or improved renal function together with urine protein excre-
tion reduced by .50% or lower than 3.5 g/day.23 Patients were 
followed up for 24–36 months after the end of treatment. All 
patients gave their informed consent for the study.
Statistics
Descriptive statistics are given as means ± standard error or 
prevalence as required. Statistical analysis was performed using 
analysis of variance for repeated measurements.  Differences 
were considered statistically significant at P,0.05.
Results
One of the 18 recruited patients (5.5%) dropped out at 
month 2 because of furosemide-unresponsive fluid retention, 
while two patients were lost at follow-up after 2 months. Six 
cases of complete remission and four cases of partial remis-
sion occurred (55.5% of responders, namely 33.3% complete 
remission and 22.2% partial remission). Complete remissions 
occurred at months at months 2 (one case), 4 (two cases), 
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and 12 (three cases) of treatment, with a median value of 
8 months.
The outcome after the end of the 12-month tetracosactide 
treatment was available in 12 patients, since three patients 
were lost at follow-up. Total remission was maintained in two 
(at 36 months of follow-up) of the six patients with complete 
remissions; in three of them, nephrotic syndrome relapsed 
(patients affected by MN, FSGS, and minimal-change 
disease), and in one nonnephrotic proteinuria occurred (MN) 
(Table 1). One patient (MN) who showed partial remission at 
the end of tetracosactide treatment presented with nephrotic 
proteinuria at 36 months (Table 1). One patient (MPGN) 
who did not respond to tetracosactide treatment, and one 
who showed partial remission, were on complete remission 
at the 24-month follow-up (Table 1).
The results of the 15 patients who completed the 
12-month study period are shown in Table 2. The reduction 
in proteinuria was significant from month 6 of treatment to 
month 12 (Figure 2 and Table 2). Serum total cholesterol 
decreased significantly (Figure 2), together with changes 
in urine protein excretion at month 6 of treatment and even 
more at month 12 (Table 2 and Figure 3). Similarly, serum 
LDL cholesterol decreased significantly from month 6 to 
month 12 (Figure 3 and Table 2). Serum albumin increased 
significantly at month 12 (Table 2).
Table 2 Proteinuria, serum albumin, eGFR (MDRD), urea, serum 
total cholesterol, LDL cholesterol, glycemia, HbA1c, potassium, 
blood pressure, and body weight pretreatment and at end of 
treatment period (mean ± standard error) in the 15 patients who 
completed the study
Pretreatment End of  
treatment
P
Proteinuria (g/d) 7.24±0.92 2.03±0.65 ,0.0001
Serum albumin (g/dL) 2.89±0.14 3.66±0.18 ,0.0001
eGFR (mL/min*1.73 m2 bs) 86.9±11.7 85.9±14.3 NS
Urea (mg/dL) 50.3±6.62 48.0±9.62 NS
Serum total  
cholesterol (mg/dL)
255±16.7 193±9.65 0.01
Serum LDL  
cholesterol (mg/dL)
168±17.7 114±6.59 0.03
Glycemia (mg/dL) 81.8±2.32 85.4±3.79 NS
HbA1c (%) 5.53±0.11 5.80±0.20 NS
Potassium (mEq/L) 4.19±0.09 4.32±0.15 NS
Body weight (kg) 71.7±3.37 74.5±5.17 NS
Systolic BP (mmHg) 127±4.00 126±4.81 NS
Diastolic BP (mmHg) 77.4±2.58 76.0±2.88 NS
Mean BP (mmHg) 93.9±2.64 92.8±3.28 NS
Abbreviations: eGFR, estimated glomerular filtration rate; MDRD, modification 
of diet in renal disease; LDL low-density lipoprotein; HbA1c, glycated hemoglobin; 
NS, not significant; BP, blood pressure.
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Renal function, serum glucose, glycated hemoglobin, 
serum potassium, urea, blood pressure, and body weight 
remained stable during treatment (Tables 1 and 2). No cases 
of hypokalemia or hyperglycemia occurred. No severe fluid 
retention unresponsive to furosemide was reported in the 
15 patients who completed the study. No admission due to 
infectious or cardiovascular events was recorded throughout 
the study period.
Discussion
Our findings show that Tetracosactide administered at a dose 
of 1 mg intramuscularly once a week for 1 year was effective 
in reducing proteinuria in patients resistant or relapsing to 
conventional treatment, with a 55.5% response rate (33.3% 
complete remission and 22.2% partial remission).
The only two recent papers that described the effect 
of synthetic ACTH in adult nephrotic patients are those 
of Berg and Arnadottir15 and Ponticelli et al.22 When com-
pared to their data, the remission rate we observed is lower. 
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However, it is noteworthy that Ponticelli et al treated only 
MN patients at their first-line treatment, and hence had a 
higher chance of favorable results with respect to resistant or 
relapsing nephrotic patients. Two patients stopped the ACTH 
therapy because of severe dizziness or fluid retention. An 
additional two patients developed glucose intolerance, one 
onychodystrophy, one patient folliculitis, and six developed 
a bronze color of the skin. These side effects did not cause 
a cessation of treatment, and they completely disappeared 
after the end of therapy.
Berg and Arnadottir15 studied a population similar to our 
series, but the prevalence of unwanted side effects was not 
reported. From their data, it emerges that one patient had a 
rapid progression to end-stage renal disease within 9 months 
of the end of the study, one patient showed a psychiatric 
syndrome, and one patient was deceased 3 months after the 
end of ACTH therapy.
The response rate we observed was similar to Bomback 
et al.24 Most of the remissions occurred within 6 months of 
therapy, and this is in keeping with Hladunewich et al.20 These 
studies employed ACTH gel, as well as the recent investigation 
on FSGS patients.25 In this study, side effects were reported 
in 21 of the 24 studied patients treated with ACTH gel. These 
consisted of fluid retention (five patients), mood alteration 
(four patients), elevated blood pressure (three patients), 
dyspepsia (two patients), hyperglycemia (one patient), upper 
respiratory tract symptoms (four patients), muscle cramps 
(four patients), polyuria (one patient), rash (two patients), 
nausea, headache, and palpitations (one patient), and wors-
ening of renal function (one patient). However, most adverse 
events were mild and transient.25
In our series, the treatment schedule was well tolerated: 
we had only one case of dropout due to fluid retention. In 
fact, sodium and water retention, potassium wasting, and 
expansion of effective circulating volume may be related 
to mineralocorticoid-receptor activation due to the ACTH-
induced cortisol production.26
The weekly dose of synthetic ACTH analog we admin-
istered was lower than that used by other authors.14–17,22 This 
lower dosage can explain the negligible occurrence of side 
effects or complications related to Tetracosactide adminis-
tration. It is important to keep in mind that the insulin-like 
effect of ACTH is related to the C-terminal sequence, and 
thus it should not occur with tetracosactide (synthetic ACTH 
1–24).27
In accordance with other studies,14,16 we observed a 
decrease in total and LDL cholesterol from month 6 to 12. 
The reduction in serum lipids occurred not only in remitting 
patients: this may be in agreement with some evidence sug-
gesting that ACTH may affect serum lipids independently of 
changes in proteinuria.16
Berg et al showed that ACTH has a pronounced lipid-low-
ering effect,14,16 mediated by modification of apolipoprotein 
metabolism. This change can restore glomerular expression 
of apolipoprotein J (clusterin), which was found to be reduced 
in MN.28 The clusterin competes in the terminal component of 
complement C5b-9 for the same receptor in podocytes with 
megalin, identified as the target of the C5b-9 injury.28
The melanocor t ins  (ACTH and α - ,  β - ,  and 
γ-melanocyte-stimulating hormone) derive from the same 
precursor –  proopiomelanocortin. The melanocortins exhibit 
anti- inflammatory and protective effects in vitro and in vivo 
in many conditions of local or systemic inflammation.9,29 
A recent report identified gene expression of the melanocortin 
receptor MC1R in podocytes, glomerular endothelial cells, 
mesangial cells, and tubular epithelial cells. The administra-
tion of MS05, a specific MC1R agonist, in rats with passive 
Heymann nephritis significantly reduced proteinuria and 
oxidative stress, and  improved podocyte morphology.7
The antiproteinuric effect of tetracosactide that we 
observed in patients unresponsive to previous steroid therapy 
seems to support the potential nonsteroidogenic mechanism 
accounting for the ACTH 1–24 therapy.30
Because of the nonsteroid-related action of ACTH, namely 
its favorable effects on podocyte structure and functions, it 
may be used in those patients for whom immunosuppressive or 
steroid treatment may not be free from risks, eg, in cases when 
renal biopsy cannot be safely performed or where the patient 
is at high risk of complications due to classical immunosup-
pressive regimens. Furthermore, there are situations where 
patients do not give their informed consent to procedures 
and/or treatments. These conditions may represent a pos-
sible indication for first-line therapy with ACTH in nephrotic 
patients. Future studies should address this point.
In summary, our investigation showed that a low dos-
age of ACTH was able to significantly reduce proteinuria 
and cholesterol in a cohort of nephrotic patients resistant 
or relapsing to immunosuppressive regimens. Although our 
regimen resulted in a lower rate of remissions with respect to 
the standard dosage, the treatment was safe and well  tolerated. 
The preliminary results of our pilot investigation need to be 
confirmed by randomized controlled studies. In addition, 
because ACTH mechanism of action and tolerability, the 
antiproteinuric effect at this low dose should be investigated 
in elderly or frail nephrotic patients who are not eligible for 
kidney biopsy or immunosuppressive protocols.
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